Cited by 498Cannabis and Cannabinoid ResearchAdenosine and Purinergic SignalingInflammatory mediators and NSAID effects

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression

Open access

Carrier, Erica J., Auchampach, John A., Hillard, Cecilia J.·2006·Proceedings of the National Academy of Sciences

Open this paper in CoChat — free account Open PDF

Abstract

The plant-derived cannabinoids delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both have immunosuppressive effects; although some effects of THC are mediated by the CB2 receptor, CB2 binds CBD weakly. In examining the effects of THC and CBD on microglial proliferation, we found that these compounds potently inhibit [3H]thymidine incorporation into a murine microglial cell line with no effect on cell cycle. Treatment with THC and CBD decreased [3H]thymidine uptake into microglia, with IC50 values that match inhibition of [3H]thymidine incorporation into DNA. CBD and, less potently, THC decreased uptake of [3H]adenosine to a similar extent as [3H]thymidine in both murine microglia and RAW264.7 macrophages. Binding studies confirm that CBD binds to the equilibrative nucleoside transporter 1 with a Ki < 250 nM. Because adenosine agonists have antiinflammatory effects, and because uptake of adenosine is a primary mechanism of terminating adenosine signaling, we tested the hypothesis that CBD is immunosuppressive because it enhances endogenous adenosine signaling. In vivo treatment with a low dose of CBD decreases TNFalpha production in lipopolysaccharide-treated mice; this effect is reversed with an A2A adenosine receptor antagonist and abolished in A2A receptor knockout mice. These studies demonstrate that CBD has the ability to enhance adenosine signaling through inhibition of uptake and provide a non-cannabinoid receptor mechanism by which CBD can decrease inflammation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.0511232103

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Reactive microgliosis
Streit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 900
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R. J., Sanvito, W. L., Lander, N., & Mechoulam, R. (2008) · Pharmacology · doi:10.1159/000137430 · Cited by 570
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T. I., Zimmer, A. M., Felder, C. C., Glass, M., & Zimmer, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00211-9 · Cited by 546
The cannabinoid system and immune modulation
Klein, T., Newton, C. A., Larsen, K. A., Lu, L. D., Perkins, I., Nong, L., & Friedman, H. P. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 533
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 530

Show all 39 references

Research works printed but not linked: 7

R. K. Razdan Pharmacol. Rev 38, 75–149 (1986).
R. G. Pertwee Cannabinoids, ed V. Di Marzo (Kluwer Academic/Plenum Publishers, New York), pp. 32–83 (2004).
A. C. Howlett, J. M. Qualy, L. L. Khachatrian Mol. Pharmacol 29, 307–313 (1986).
B. Desoize, C. Leger, J. C. Jardillier, G. Nahas Adv. Biosci 22–23, 145–159 (1978).
B. Desoize, C. Leger, G. Nahas C. R. Hebd. Seances Acad. Sci. D 287, 1441–1444 (1978).
P. G. Smith, H. D. Thomas, H. C. Barlow, R. J. Griffin, B. T. Golding, H. Calvert, D. R. Newell, N. J. Curtin Clin. Cancer Res 7, 2105–2113 (2001).
A. S. Gordon, L. Nagy, D. Mochly-Rosen, I. Diamond Biochem. Soc. Symp 56, 117–136 (1990).

Sorted by citations

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9 ‐tetrahydrocannabinol, cannabidiol and Δ 9 ‐tetrahydrocannabivarin
Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 2,047
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
Izzo, A. A., Borrelli, F., Capasso, R., Marzo, V. D., & Mechoulam, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.006 · Cited by 879
Antioxidative and Anti-Inflammatory Properties of Cannabidiol
Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019) · Antioxidants · doi:10.3390/antiox9010021 · Cited by 889
Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 664
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622
Molecular Targets of Cannabidiol in Neurological Disorders
Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 602
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.059 · Cited by 573
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558
Cannabinoid and cannabinoid‐like receptors in microglia, astrocytes, and astrocytomas
Stella, N. (2010) · Glia · doi:10.1002/glia.20983 · Cited by 556
Cannabidiol—recent advances
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 529
From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 505
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475
Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421
Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer’s Disease
Martín-Moreno, A. M., Reigada, D., Ramírez, B. G., Mechoulam, R., Innamorato, N. G., Cuadrado, A., & CEBALLOS, M. L. D. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071290 · Cited by 410
TRPV2 Is Activated by Cannabidiol and Mediates CGRP Release in Cultured Rat Dorsal Root Ganglion Neurons
Qin, N., Neeper, M. P., Liu, Y., Hutchinson, T. L., Lubin, M. L., & Flores, C. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0504-08.2008 · Cited by 403
Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads
Russo, E. B., & Marcu, J. P. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.03.004 · Cited by 403
Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats
Campos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
Fernández‐Ruíz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R. G., Mechoulam, R., & Martínez-Orgado, J. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04341.x · Cited by 364
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312
Adenosine signaling and function in glial cells
Boison, D., Chen, J., & Fredholm, B. B. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.131 · Cited by 319
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
Mlost, J., Bryk, M., & Starowicz, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228870 · Cited by 315
Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers
Martín‐Santos, R., Crippa, J. A. S., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M. L., Langohr, K., Farré, M., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884780 · Cited by 298
Immune Responses Regulated by Cannabidiol
Nichols, J. M., & Kaplan, B. L. F. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0073 · Cited by 308
Cannabinoids in the management of difficult to treat pain
Russo, E. B. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1928 · Cited by 300
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
Mecha, M., Feliú, A., Iñigo, P. M., Mestre, L., Carrillo-Salinas, F. J., & Guaza, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.06.016 · Cited by 285
Cannabinoids and Epilepsy
Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0375-5 · Cited by 292
The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic–ischemic brain damage in mice is mediated by CB2 and adenosine receptors
Castillo, A., Tolón, M. R., Fernández-Ruiz, J., Romero, J., & Martinez-Orgado, J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.10.023 · Cited by 279
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
Devinsky, O., Nabbout, R., Miller, I., Laux, L., Żołnowska, M., Wright, S., & Roberts, C. (2018) · Epilepsia · doi:10.1111/epi.14628 · Cited by 275
Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
El‐Alfy, A. T., Ivey, K., Robinson, K., Ahmed, S. A., Radwan, M. M., Slade, D., Khan, I. A., ElSohly, M. A., & Ross, S. A. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.004 · Cited by 278
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
Oláh, A., Tóth, B. I., Borbíró, I., Sugawara, K., Szöllõsi, A. G., Czifra, G., Pál, B., Ambrus, L., Kloepper, J., Camera, E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci64628 · Cited by 268
Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats
de Bitencourt, R. M., Pamplona, F. A., & Takahashi, R. N. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.001 · Cited by 277
Diversity of molecular targets and signaling pathways for CBD
de Almeida, D. L., & Devi, L. A. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.682 · Cited by 284
Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+Levels
Ryan, D., Drysdale, A. J., Lafourcade, C., Pertwee, R. G., & Platt, B. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4212-08.2009 · Cited by 258
Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT1A somatodendritic autoreceptors in the dorsal raphe nucleus
Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi‐Goffer, S., Fletcher, P., Mechoulam, R., Pertwee, R., & Parker, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01621.x · Cited by 255
Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science
Baron, E. P. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 268
Cannabinoids: Therapeutic Use in Clinical Practice
Pagano, C., Navarra, G., Coppola, L., Avilia, G., Bifulco, M., & Laezza, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063344 · Cited by 261
Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites
Turcotte, C., Chouinard, F., Lefebvre, J. S., & Flamand, N. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ru0115-021r · Cited by 258
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
Jones, N. A., Glyn, S., Akiyama, S., Hill, T. D. M., Hill, A. J., Weston, S. E., Burnett, M. D. A., Yamasaki, Y., Stephens, G. J., Whalley, B. J., et al. (2012) · Seizure · doi:10.1016/j.seizure.2012.03.001 · Cited by 257
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
Booz, G. W. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.007 · Cited by 254
Molecular Pharmacology of Phytocannabinoids
Turner, S. E., Williams, C. M., Iversen, L. L., & Whalley, B. J. (2017) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-319-45541-9_3 · Cited by 264
Mechanisms in the Bed Nucleus of the Stria Terminalis Involved in Control of Autonomic and Neuroendocrine Functions: A Review
Crestani, C. C., Alves, F. H. F., Gomes, F. V., Resstel, L. B. M., Corrêa, F. M. D. A., & Herman, J. P. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311020002 · Cited by 259
Cannabinoids in the Treatment of Epilepsy
Friedman, D. J., & Devinsky, O. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1407304 · Cited by 243
Adenosine kinase, epilepsy and stroke: mechanisms and therapies
Boison, D. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.10.008 · Cited by 243
Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder
Hill, M. N., Campolongo, P., Yehuda, R., & Patel, S. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.162 · Cited by 250
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233
Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based Medicine
Russo, E. B., Guy, G. W., & Robson, P. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790150 · Cited by 228
Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
Perucca, E. (2017) · Journal of Epilepsy Research · doi:10.14581/jer.17012 · Cited by 243
The adenosine kinase hypothesis of epileptogenesis
Boison, D. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.12.002 · Cited by 224
Endocannabinoid system and mood disorders: Priming a target for new therapies
Micale, V., Marzo, V. D., Šulcová, A., Wotjak, C. T., & Drago, F. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.002 · Cited by 224
Equilibrative nucleoside transporters—A review
Boswell-Casteel, R. C., & Hays, F. A. (2016) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2016.1210805 · Cited by 215
The Pharmacological Case for Cannabigerol
Nachnani, R., Raup‐Konsavage, W. M., & Vrana, K. E. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000340 · Cited by 227
Cannabinoids: Occurrence and Medicinal Chemistry
Appendino, G., Chianese, G., & Taglialatela‐Scafati, O. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794940888 · Cited by 209
Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?
Martínez, V., Iriondo‐DeHond, A., Borrelli, F., Capasso, R., del Castillo, M. D., & Abalo, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093067 · Cited by 197
Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: Role for the adenosine A2A receptor
Ribeiro, A., Ferraz-de-Paula, V., Pinheiro, M. L., Vitoretti, L. B., Mariano-Souza, D. P., Quinteiro-Filho, W. M., Akamine, A. T., de Almeida, V. I., Quevedo, J., Dal‐Pizzol, F., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.12.043 · Cited by 190
Adenosine, caffeine, and sleep–wake regulation: state of the science and perspectives
Reichert, C. F., Deboer, T., & Landolt, H. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13597 · Cited by 183
“Nevertheless, it is interesting to note that one of the most abundant components in the native cannabis plant, cannabidiol, inhibits the ENT1 (Carrier et al., 2006).”
Background
Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort
Baron, E. P., Lucas, P., Eades, J., & Hogue, O. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0862-2 · Cited by 188
Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy
McGrath, S., Bartner, L. R., Rao, S., Packer, R. A., & Gustafson, D. L. (2019) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.254.11.1301 · Cited by 200
Non‐psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action
Maione, S., Piscitelli, F., Gatta, L., Vita, D. D., PETROCELLIS, L. D., Palazzo, E., de Novellis, V., & Marzo, V. D. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01063.x · Cited by 186
Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders
Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175
Cannabidivarin is anticonvulsant in mouse and rat
Hill, A. G., Mercier, M., Hill, T., Glyn, S., Jones, N., Yamasaki, Y., Futamura, T., Duncan, M., Stott, C., Stephens, G. J., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02207.x · Cited by 179
Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy
Franco, V., & Perucca, E. (2019) · Drugs · doi:10.1007/s40265-019-01171-4 · Cited by 180
Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage
Hurd, Y. L., Yoon, M. J., Manini, A. F., Hernandez, S. H., Olmedo, R., Östman, M., & Jutras‐Aswad, D. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0373-7 · Cited by 171
Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death
Rimmerman, N., Ben-Hail, D., Porat, Z., Juknat, A., Kozela, E., Daniels, M. P., Connelly, P. S., Leishman, E., Bradshaw, H. B., Shoshan‐Barmatz, V., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.471 · Cited by 164
Molecular and Cellular Mechanisms of Action of Cannabidiol
Naya, N. M., Kelly, J., Corna, G., Golino, M., Abbate, A., & Toldo, S. A. (2023) · Molecules · doi:10.3390/molecules28165980 · Cited by 169
Cannabidiol administration after hypoxia–ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function
Pazos, M. R., Cinquina, V., Gómez, A., Layunta, R., Santos, M., Fernández‐Ruíz, J., & Martínez-Orgado, J. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.034 · Cited by 151
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Osborne, A. L., Solowij, N., & Weston–Green, K. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.012 · Cited by 154
THC and CBD: Similarities and differences between siblings
Stella, N. (2023) · Neuron · doi:10.1016/j.neuron.2022.12.022 · Cited by 165
Mediation of Cannabidiol Anti-inflammation in the Retina by Equilibrative Nucleoside Transporter and A 2A Adenosine Receptor
Liou, G. I., Auchampach, J. A., Hillard, C. J., Zhu, G., Yousufzai, B. K., Mian, S., Khan, S. H., & Khalifa, Y. M. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2196 · Cited by 148
Self-citation
Cannabidiol—from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer
Kis, B., Ifrim, F. C., Buda, V. O., Avram, Ș., Pavel, I. Z., Antal, D., Păunescu, V., Dehelean, C. A., Ardelean, F., Diaconeasa, Z. M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235905 · Cited by 148
From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases
Cassano, T., Villani, R., Pace, L., Carbone, A., Bukke, V. N., Orkisz, S., Avolio, C., & Serviddio, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00124 · Cited by 156
Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1and adenosine A2Areceptors
Sagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., & Fernández‐Ruiz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05717.x · Cited by 147
Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats
Lemos, J. I., Resstel, L. B., & Guimarães, F. S. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.09.045 · Cited by 146
Cannabidiol arrests onset of autoimmune diabetes in NOD mice
Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., & Gallily, R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.029 · Cited by 147
Adenosinergic signaling in epilepsy
Boison, D. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.046 · Cited by 144
Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors
Casarotto, P. C., Gomes, F. V., Resstel, L. B. M., & Guimarães, F. S. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833b33c5 · Cited by 141
Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products
Anderson, G. D., & Chan, L. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0400-9 · Cited by 141
The emerging role of the endocannabinoid system in cardiovascular disease
Pacher, P., & Steffens, S. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0145-8 · Cited by 142
Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects
Marco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 139
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135
Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism
Hayakawa, K., Mishima, K., Hazekawa, M., Sano, K., Irie, K., Orito, K., Egawa, T., Kitamura, Y., Uchida, N., Nishimura, R., et al. (2007) · Brain Research · doi:10.1016/j.brainres.2007.09.090 · Cited by 134
The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT)
Kaplan, B. L. F., Springs, A. E. B., & Kaminski, N. E. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.06.022 · Cited by 138
Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury
Durst, R. Y., Danenberg, H. D., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Beeri, R., Pugatsch, T., Tarsish, E., & Lotan, C. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00098.2007 · Cited by 134
Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges
Oláh, A., Szekanecz, Z., & Bı́ró, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01487 · Cited by 123
Cannabidiol ameliorates cognitive and motor impairments in bile‐duct ligated mice via 5‐HT1A receptor activation
Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., & Berry, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00589.x · Cited by 125
Inclusion complexes of cannabidiol with β-cyclodextrin and its derivative: Physicochemical properties, water solubility, and antioxidant activity
Li, H., Chang, S., Chang, T., You, Y., Wang, X. A., Wang, L., Yuan, X., Tan, M., Wang, P., Xu, P., et al. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.116070 · Cited by 119
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels
Sales, A. J., Crestani, C. C., Guimarães, F. S., & Joca, S. R. L. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.06.002 · Cited by 118
Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity
Fouad, A. A., Albuali, W. H., Al-Mulhim, A. S., & Jresat, I. (2013) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2013.04.018 · Cited by 116
Microarray and Pathway Analysis Reveal Distinct Mechanisms Underlying Cannabinoid-Mediated Modulation of LPS-Induced Activation of BV-2 Microglial Cells
Juknat, A., Pietr, M., Kozela, E., Rimmerman, N., Levy, R., Gao, F., Coppola, G., Geschwind, D. H., & Vogel, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061462 · Cited by 121
Social Stress and Psychosis Risk: Common Neurochemical Substrates?
Mizrahi, R. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.274 · Cited by 122
Cannabidiol for neurodegenerative disorders: A comprehensive review
Bhunia, S., Kolishetti, N., Yndart, A., Vashist, A., & Nair, M. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989717 · Cited by 121
Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial
Patel, A. D., Mazurkiewicz‐Bełdzińska, M., Chin, R., Gil‐Nagel, A., Gunning, B. W., Halford, J. J., Mitchell, W. G., Perry, M. S., Thiele, E. A., Weinstock, A., et al. (2021) · Epilepsia · doi:10.1111/epi.17000 · Cited by 120

Authors: Carrier, E. J., Auchampach, J. A., & Hillard, C. J.
Affiliations: Medical College of Wisconsin (US)
ORCID: Carrier, Erica J.
Auchampach, John A.
Hillard, Cecilia J.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2006-05-16
Volume: 103
Issue: 20
Pages: 7895-7900
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0511232103
OpenAlex: W2067960394
Cited by: 497
References: 39
Citations by year: 2026: 20 · 2025: 30 · 2024: 29 · 2023: 33 · 2022: 40 · 2021: 33 · 2020: 40 · 2019: 32 · 2018: 19 · 2017: 25 · 2016: 20 · 2015: 19 · 2014: 11 · 2013: 20 · 2012: 24
FWCI: 14.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
National Heart, Lung, and Blood Institute (HL 077707, R01HL077707)
National Institute on Drug Abuse (R01DA009155, DA 16967, DA09155, R01DA016967)
National Institute of Neurological Disorders and Stroke (NS041314, R01NS041314)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords: cannabidiol, delta-9-tetrahydrocannabinol, equilibrative nucleoside transporter 1, adenosine uptake, adenosine signaling, adenosine A2A receptor, microglial proliferation, macrophages, TNF-α, lipopolysaccharide-induced inflammation, anti-inflammatory activity
MeSH terms: Rimonabant, Adenosine, Animals, Camphanes, Cannabidiol, Cell Line, DNA, Immunosuppression Therapy, Lipopolysaccharides, Male, Mice, Inbred C57BL, Piperidines, Psychotropic Drugs, Pyrazoles, Dronabinol, Thymidine, Tumor Necrosis Factor-alpha, Microglia, Nucleoside Transport Proteins, Equilibrative Nucleoside Transporter 1, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks